Search the webpage

Created by Simon Kaja on   July 11, 2018   in category: Scientific publications

Trabodenoson, an alpha1 adrenergic agonist, shows preclinical efficacy in a preclinical model for dry eye syndrome, according to a study co-authored by Experimentica Ltd.

According to the results of a study published in the June 2018 issue of Investigative Ophthalmology and Vision Research, trabodenoson eye drops reduced attenuated hallmark signs of dry-eye disease pathology, including corneal surface inflammation, lacrimal gland infiltration by immune cells and loss of mucin-producing goblet cells in the conjunctiva.

The study, conducted in collaboration with Inotek Pharmaceuticals Corp., K&P Scientific LLC and Loyola University Chicago, compared the preclinical efficacy with a marketed formulation of ophthalmic cyclosporine emulsion and concluded that trabodenoson showed similar or better preclinical efficacy, supporting the development of A1R-targeting pharmaceuticals for DED.

Experimentica Ltd. is a global contract research organization specialized in ocular models. Headquartered in Kuopio, Finland, Experimentica Ltd. focuses on Advancing Ophthalmic Drug DiscoveryTM by offering an industry-leading portfolio for ophthalmic drug development.

Contact for media enquiries: 

Dr. Simon Kaja
Chief Scientific Officer
Experimentica Ltd.
Phone: +1 (844) 393-49393
Email: kaja@experimentica.com

Leave a Comment

LATEST NEWS

Meet Experimentica Ltd. in Vienna at the EURETINA 2018, Congress

News
[Kuopio, Finland and Chicago, USA – September 18th, 2018] – Experimentica Ltd. announces its attendance at the participation in the ... Read More

Experimentica Ltd. Presents at the ISER in Belfast, Northern Ireland

News
Experimentica Ltd. announces its participation in the scientific sessions at the biennial meeting of the International Society of Eye Research ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!